This is a snippet of the transcript, sign up to read more.
Enterprises already had a ServiceNow relationship within the ITO function, so in a way they had an inroad into the enterprise. Their product was also ready from a workflow capability perspective. It is no different than building the business because you leverage workflow capability, process orchestration and integration with ERPs. They already had the CMDB setup with the hierarchy and org structure, which is all replicated so you can also leverage that for HR workflows. Those are the reasons why they have the right to win in this space, compared to a pure play. In my previous life, I implemented a pure play workflow engine but it is a technology layer and nothing else. Everything for you to hook on and connect to would be 100% custom.
This is a snippet of the transcript, sign up to read more.
I consider that an opportunity. Another way to answer your question is if I have a million incremental dollars on R&D, should I build commercial workflows to try win in this space, or choose to win in the observability space? There is no doubt in my mind that every dollar they have should be put in this space instead of changing their focus and trying to be everything to everyone.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research